Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSANASDAQ:FWPAYNASDAQ:VCNXNASDAQ:ZYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.04+1.5%$2.12$1.55▼$5.59$14.29M0.41491,932 shs3,689 shsFWPAYForward Pharma A/S$300.00$424.38$1.43▼$5.33$6M-42.677 shs11 shsVCNXVaccinex$0.71$0.81$0.25▼$8.90$1.85M1.156,271 shs54 shsZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech0.00%+4.35%+0.49%-18.40%-52.11%FWPAYForward Pharma A/S0.00%0.00%0.00%0.00%0.00%VCNXVaccinex0.00%-10.92%+2.90%+24.47%-88.42%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDSAEdesa Biotech3.1994 of 5 stars3.55.00.00.02.21.70.6FWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 3.00Buy$21.00929.41% UpsideFWPAYForward Pharma A/S 0.00N/AN/AN/AVCNXVaccinex 0.00N/AN/AN/AZYNEZynerba Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/AN/AVCNXVaccinex$388K4.76N/AN/A($2.59) per share-0.27ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)FWPAYForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AVCNXVaccinex-$20.25M-$48.27N/A∞N/AN/AN/A-383.58%8/12/2025 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest EDSA, FWPAY, ZYNE, and VCNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AFWPAYForward Pharma A/SN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A15.7215.72FWPAYForward Pharma A/SN/AN/AN/AVCNXVaccinexN/A0.770.77ZYNEZynerba PharmaceuticalsN/A3.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%FWPAYForward Pharma A/S2.63%VCNXVaccinex50.11%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%FWPAYForward Pharma A/S71.47%VCNXVaccinex51.50%ZYNEZynerba Pharmaceuticals13.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableFWPAYForward Pharma A/SN/A20,0007,000Not OptionableVCNXVaccinex402.60 million1.26 millionNo DataZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableEDSA, FWPAY, ZYNE, and VCNX HeadlinesRecent News About These CompaniesHarmony Biosciences: If It Ain't BrokeJune 5, 2025 | seekingalpha.comUS Penny Stocks To Watch In October 2024October 28, 2024 | uk.finance.yahoo.comDiscover 3 US Penny Stocks With Market Caps Over $70MOctober 24, 2024 | uk.finance.yahoo.comAtea Pharmaceuticals Leads The Charge In US Penny Stocks SpotlightOctober 22, 2024 | uk.finance.yahoo.comGW Pharma's cannabis-derived epilepsy drug approved in EUOctober 7, 2024 | pharmaphorum.comFragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery PartnersJuly 31, 2024 | globenewswire.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comWhy Shares of Harmony Bioscience Are Falling on FridayOctober 13, 2023 | fool.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | markets.businessinsider.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | finance.yahoo.comH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)October 10, 2023 | knoxdaily.comAnalysts: ZYNE stock price target of $1.25 in 12 monthsOctober 5, 2023 | knoxdaily.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsOctober 4, 2023 | finance.yahoo.comExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)October 2, 2023 | knoxdaily.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023September 29, 2023 | finance.yahoo.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 27, 2023 | bizjournals.comZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the RiseSeptember 25, 2023 | knoxdaily.comZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. WainwrightSeptember 20, 2023 | knoxdaily.comNegative sentiment towards ZYNE reflected in surge in short interestSeptember 15, 2023 | knoxdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDSA, FWPAY, ZYNE, and VCNX Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.02 +0.01 (+0.55%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Forward Pharma A/S NASDAQ:FWPAYForward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.Vaccinex NASDAQ:VCNX$0.71 0.00 (0.00%) As of 06/18/2025Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.Zynerba Pharmaceuticals NASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
